Literature DB >> 11526992

Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats.

F Tascedda1, J M Blom, N Brunello, K Zolin, M Gennarelli, A Colzi, D Bravi, S Carra, G Racagni, M A Riva.   

Abstract

BACKGROUND: A disturbance in glutamate neurotransmission has been hypothesized in schizophrenia. Hence, the beneficial effects of pharmacological treatment may be related to adaptive changes taking place in this neurotransmitter system.
METHODS: In this study, we investigated the modulation of ionotropic and metabotropic glutamate receptors in the rat brain following acute or chronic exposure to the novel antipsychotic olanzapine.
RESULTS: In accordance with the clear distinction between classical and atypical drugs, olanzapine did not alter glutamate receptor expression in striatum. Chronic, not acute, exposure to olanzapine was capable of up-regulating hippocampal mRNA levels for GluR-B and GluR-C, two alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA)-forming subunits. This effect could be relevant for the improvement of schizophrenic alterations, which are thought to depend on dysfunction of the glutamatergic transmission within the hippocampal formation. We also found that the expression of group II glutamate metabotropic receptors was up-regulated in the frontal cortex after chronic exposure to clozapine, and to a lesser extent olanzapine, but not with haloperidol.
CONCLUSIONS: The adaptive mechanisms taking place in glutamatergic transmission might prove useful in ameliorating some of the dysfunction observed in the brain of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526992     DOI: 10.1016/s0006-3223(01)01135-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  14 in total

1.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 2.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

3.  Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.

Authors:  Jeffrey R Bishop; Del D Miller; Vicki L Ellingrod; Timothy Holman
Journal:  Hum Psychopharmacol       Date:  2011-01       Impact factor: 1.672

4.  Elevated glutamate, glutamine and GABA levels and reduced taurine level in a schizophrenia model using an in vitro proton nuclear magnetic resonance method.

Authors:  Jingyu Yang; Huiling Guo; Dandan Sun; Jia Duan; Xiaoping Rao; Fuqiang Xu; Anne Manyande; Yanqing Tang; Jie Wang; Fei Wang
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

Review 5.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

6.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

7.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

8.  Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats.

Authors:  Ottavio Gandolfi; Manuela Voltattorni; Renato Gaggi; Rossella Dall'Olio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

9.  Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia.

Authors:  Stella Dracheva; William Byne; Benjamin Chin; Vahram Haroutunian
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

10.  Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.

Authors:  Natalie Matosin; Francesca Fernandez-Enright; Elisabeth Frank; Chao Deng; Jenny Wong; Xu-Feng Huang; Kelly A Newell
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.